Key Takeaways:
UOB Kay Hian slashed its price target for Ali Health (00241.HK) to HKD6 from HKD7.8 after the company trimmed its fiscal 2026 profit growth forecast to fund greater investment in artificial intelligence and new drugs.
The bank maintained its Buy rating, citing long-term potential despite the near-term profit impact. A separate report from Goldman Sachs recently cut its target price on the stock to HKD4.8 with a Neutral rating, flagging similar concerns over AI investment weighing on profits.
Ali Health recently lowered its fiscal 2026 adjusted net profit growth guidance to a range of 10-20 percent year-over-year, a significant reduction from the previous target of 20-30 percent. The change reflects a strategic decision to allocate more capital towards developing its innovative drug business and integrating artificial intelligence.
The lowered guidance and subsequent analyst downgrades introduce uncertainty for Ali Health's shares, which have a short-selling ratio of nearly 35 percent. Investors are weighing the potential for long-term growth from AI and new drugs against the certainty of lower near-term profitability.
The move signals a strategic pivot that prioritizes long-term market share over short-term earnings. Investors will be closely watching the company's next earnings report for early returns on its AI and drug investments.
This article is for informational purposes only and does not constitute investment advice.
